期刊
JOURNAL OF NEUROSCIENCE
卷 37, 期 48, 页码 11731-11743出版社
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.1395-17.2017
关键词
lipid mediators; Maresin-1; neuroprotection; resolution; spinal cord injury
资金
- Spanish Ministry of Economy and Competitiveness [SAF2010-17851, SAF2013-48431-R]
- International Foundation for Research in Paraplegia
- Fondo de Investigacion Sanitaria of Spain (TERCEL)
- Fondo de Investigacion Sanitaria of Spain (CIBERNED)
- Wings for Life Spinal Cord Research Foundation
- Era-Net-NEURON Program of the European Union (SILENCE Grant) [01EW170A]
- NIDILRR [90SI5020]
- W.E. Hunt & C.M. Curtis Endowment
- National Institutes of Health [EY026082]
- NIDILRR [911874, 90SI5020] Funding Source: Federal RePORTER
Resolution of inflammation is defective after spinal cord injury (SCI), which impairs tissue integrity and remodeling and leads to functional deficits. Effective pharmacological treatments for SCI are not currently available. Maresin 1 (MaR1) is a highly conserved specialized proresolving mediator (SPM) hosting potent anti-inflammatory and proresolving properties with potent tissue regenerative actions. Here, we provide evidence that the inappropriate biosynthesis of SPM in the lesioned spinal cord hampers the resolution of inflammation and leads to deleterious consequences on neurological outcome in adult female mice. We report that, after spinal cord contusion injury in adult female mice, the biosynthesis of SPM is not induced in the lesion site up to 2 weeks after injury. Exogenous administration of MaR1, a highly conserved SPM, propagated inflammatory resolution after SCI, as revealed by accelerated clearance of neutrophils and a reduction in macrophage accumulation at the lesion site. In the search of mechanisms underlying the proresolving actions of MaR1 in SCI, we found that this SPM facilitated several hallmarks of resolution of inflammation, including reduction of proinflammatory cytokines (CXCL1, CXCL2, CCL3, CCL4, IL6, and CSF3), silencing of major inflammatory intracellular signaling cascades (STAT1, STAT3, STAT5, p38, and ERK1/2), redirection of macrophage activation toward a prorepair phenotype, and increase of the phagocytic engulfment of neutrophils by macrophages. Interestingly, MaR1 administration improved locomotor recovery significantly and mitigated secondary injury progression in a clinical relevant model of SCI. These findings suggest that proresolution, immunoresolvent therapies constitute a novel approach to improving neurological recovery after acute SCI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据